Idiopathic Pulmonary Fibrosis (IPF) is the archetypical progressive fibrotic interstitial lung disease (ILD). As the morbidity and mortality rates associated with IPF remain high, prompt treatment of IPF is critical to safeguard patients’ lung function, reduce the risk of acute exacerbations, and improve outcomes.